These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15681552)

  • 21. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective.
    Fisher B; Redmond CK; Fisher ER
    J Clin Oncol; 2008 May; 26(13):2068-71. PubMed ID: 18445835
    [No Abstract]   [Full Text] [Related]  

  • 23. Core biopsy is accurate in determining the hormone receptor status of early breast cancer.
    Harris K; Morafa I; Thomas V; Mokbel K
    Am J Surg; 2004 Apr; 187(4):568; author reply 568. PubMed ID: 15041517
    [No Abstract]   [Full Text] [Related]  

  • 24. [Steroid receptors and NK cell activity in patients with breast cancer].
    Konjević G; Branković-Magić M; Nikolić-Vukosavljević D; Spuzić I
    Srp Arh Celok Lek; 1994; 122(5-6):139-42. PubMed ID: 17977410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Should immunohistochemistry be used to evaluate estrogen and progesterone receptors in breast cancers?].
    Balaton AJ; Zafrani B
    Ann Pathol; 1996; 16(2):78-80. PubMed ID: 8767672
    [No Abstract]   [Full Text] [Related]  

  • 26. Triple negative breast cancer: clinicopathological characteristics and treatment strategies.
    Akiyama F; Iwase H
    Breast Cancer; 2009; 16(4):252-3. PubMed ID: 19506994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. It is not time to stop progesterone receptor testing in breast cancer.
    Colomer R; Beltran M; Dorcas J; Cortes-Funes H; Hornedo J; Valentin V; Vargas C; Mendiola C; Ciruelos E
    J Clin Oncol; 2005 Jun; 23(16):3868-9; author reply 3869-70. PubMed ID: 15923595
    [No Abstract]   [Full Text] [Related]  

  • 28. [Endocrine therapies in breast cancer].
    Schnürch HG
    Gynakologe; 1993 Apr; 26(2):107-17. PubMed ID: 7685309
    [No Abstract]   [Full Text] [Related]  

  • 29. Steroid receptors in breast cancer.
    Cowan K; Lippman M
    Arch Intern Med; 1982 Feb; 142(2):363-6. PubMed ID: 7036926
    [No Abstract]   [Full Text] [Related]  

  • 30. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
    Mann GB; Fahey VD; Feleppa F; Buchanan MR
    J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Determination of cytosolic receptors for estradiol and progesterone in 137 cases of breast cancer: technics, clinical and histopathological correlations].
    Dewailly D; Bonneterre J; Vandewalle B; Delobelle A; Lefebvre J; Demaille AC
    Lille Med; 1980 Nov; 25(9):496-501. PubMed ID: 7453486
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential chemotherapy options in the triple negative subtype of breast cancer.
    Altundag K; Harputluoglu H; Aksoy S; Gullu IH
    J Clin Oncol; 2007 Apr; 25(10):1294-5; author reply 1295-6. PubMed ID: 17401026
    [No Abstract]   [Full Text] [Related]  

  • 33. [Endocrine therapy of breast cancer].
    Bassalyk LS; Murav'eva NI; Smirnova KD; Kuz'mina ZV
    Sov Med; 1981; (12):54-9. PubMed ID: 7038903
    [No Abstract]   [Full Text] [Related]  

  • 34. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.
    Sharangpani GM; Joshi AS; Porter K; Deshpande AS; Keyhani S; Naik GA; Gholap AS; Barsky SH
    J Microsc; 2007 Jun; 226(Pt 3):244-55. PubMed ID: 17535263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
    Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
    Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can systematic research of hormone and growth factor receptors contribute to the recognition of acute and chronic types of breast cancer, of their specific mammary dysplasias, and of specific treatments?
    Mathé G
    Biomed Pharmacother; 1995; 49(9):385-8. PubMed ID: 8746074
    [No Abstract]   [Full Text] [Related]  

  • 38. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
    Ellis MJ
    J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
    [No Abstract]   [Full Text] [Related]  

  • 39. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 40. Estrogen receptors and advanced breast cancer.
    Reich SD
    Cancer Nurs; 1981 Jun; 4(3):247-8. PubMed ID: 6909045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.